Healthcare professionals are increasingly adopting value-based care models, and turning to strong patient engagement tactics to drive success. However, the language used in patient engagement and value-based care discussions is sometimes nebulous, difficult to understand, or overlapping with other industry keywords.
In alphabetical order, PatientEngagementHIT.com defines the latest patient engagement buzzwords pertaining to the current rise of value-based care initiatives.
Benefit-risk assessment is at the heart of what we do to ensure that Americans have access to medical products that are safe, effective and meet their needs.
But we’re also deeply aware that serious chronic illnesses aren’t monolithic. Patient perception of the benefits and risks of different treatment options can vary based on the stage of the disease, the age of onset, alternative therapies available to treat the disease (if any) and whether a novel therapy improves a patient’s ability to function normally, slows the rate of disease progression or impacts other aspects of a patient’s quality of life.
The FDA Patient Focused Drug Development meeting held Monday, March 19, 2018 was a game changer for me – and the life sciences industry. The FDA, specifically, the Center for Drug Evaluation and Research (CDER) Office of Strategic Initiatives is responsible for the implementation of the 21st Century Cures Act. This meeting was the second in a series of workshops to implement a four-stage plan to support the Cures Act. At this workshop, the lead, Theresa Mullins, PhD, Associate Director for Strategic Initiatives, made it clear that the goal of the plan is to ensure the patient has input to the full breadth of drug development – from pre-IND through commercial. This is music to my ears! It stunned me that the FDA has evolved to this degree – and it is going to push the industry.